[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344827-105":59,"doc-detail-344827-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pulmonary-arterial-hypertension-and-cancer-unveiling-parallels-in-epidemiology-clinical-pathways-and-therapeutic-strategies","Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies","","Pulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses, yet PAH parallels may be underrecognized due to PAH’s rarity. This study assessed similarities between PAH and cancer across epidemiology, clinical features, therapeutic landscape, and healthcare resource utilization (HCRU). A four-step method applied inclusion/exclusion criteria, categorized comparable characteristics, performed a targeted literature review, and ranked analogs via absolute differences. Fourteen cancers met criteria; well-differentiated thyroid cancer matched most characteristics. Multiple analogs highlighted PAH’s multidimensional complexity and its overlap with oncology, supporting improved recognition of clinical, therapeutic, and HCRU implications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pulmonary-arterial-hypertension-and-cancer-unveiling-parallels-in-epidemiology-clinical-pathways-and-therapeutic-strategies/344827/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pulmonary-arterial-hypertension-and-cancer-unveiling-parallels-in-epidemiology-clinical-pathways-and-therapeutic-strategies/344827.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why were parallels between PAH and cancer studied?","Question",{"text":112,"@type":113},"PAH and cancer both have high mortality and complex prognoses, but PAH parallels may be underrecognized because PAH is relatively rare. Identifying similarities across domains could improve recognition among healthcare stakeholders.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study identify cancer analogs for PAH?",{"text":117,"@type":113},"The four-step approach used inclusion/exclusion criteria to select potential analogs, categorized comparison characteristics (epidemiologic, clinical, therapeutic landscape, and HCRU), extracted data via a targeted literature review, and ranked similarity using absolute differences between cancer and PAH characteristics.",{"name":119,"@type":110,"acceptedAnswer":120},"Were any cancers found to fully mirror PAH?",{"text":121,"@type":113},"No single cancer fully mirrored PAH. Instead, multiple analogs differed by domain, collectively reinforcing PAH’s multidimensional complexity and overlap with oncological conditions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344827,1790987070,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article  \nPulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies  \nKarim EI-Kersh 1, Nadine Zawadzki 2, Catelyn Coyle 3, Shurui Zhang 4, Dhruv Dalal 4, Anna Watzker 3, Dominik Lautsch 3 and Jason Shafrin 2, *  \nAcademic Editor: Mondher Toumi  \nReceived: 3 December 2025  \nRevised: 8 January 2026  \nAccepted: 23 January 2026  \nPublished: 6 February 2026  \nCopyright: © 2026 by the authors. Published by MDPI on behalf of the Market Access Society. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution  \n(CC BY) license.  \n1 College of Medicine, University of Arizona, Phoenix, AZ 85004, USA  \n2 Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA 90071, USA  \n3 Merck & Co., Inc., Rahway, NJ 07065, USA  \n4 Center for Healthcare Economics and Policy, FTI Consulting, Washington, DC 20004, USA  \n* [Correspondence: jason.shafrin@fticonsulting.com](Correspondence: jason.shafrin@fticonsulting.com)  \nAbstract  \nPulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses. Due to PAH’s rarity, these parallels may be underrecognized by healthcare stakeholders. This study explored similarities between PAH and cancer across epidemiological, clinical, therapeutic, and healthcare resource utilization (HCRU) considerations. A four-step approach was employed: (1) inclusion/exclusion criteria were applied to identify potential PAH cancer analogs; (2) characteristics for comparison were categorized as epidemiologic, clinical, therapeutic landscape, and HCRU; (3) a targeted literature review extracted data on disease characteristics; (4) a similarity ranking was calculated as the absolute difference between each cancer’s and PAH’s characteristics. Fourteen cancers met the inclusion criteria. Well-differentiated thyroid cancer (WDTC) had the highest number (5) of characteristics closest to PAH. WDTC and medullary thyroid cancer were most similar to PAH in epidemiology; gastrointestinal stromal tumor was most similar in clinical and HCRU characteristics, and anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer and renal cell carcinoma were most similar in therapeutic landscape. Although no single cancer fully mirrors PAH, the identification of multiple analogs underscores PAH’s multidimensional complexity and confirms its overlap with oncological conditions. Cancer analogs could serve as a valuable framework for enhancing recognition of PAH’s clinical, therapeutic, and HRCU implications among healthcare stakeholders.  \nKeywords: cancer; disease analog; evidence synthesis; pulmonary arterial hypertension  \n1. Introduction  \nPulmonary hypertension (PH) is characterized by elevated pressure within the pulmonary artery and is classified into five diagnostic groups. Group 2 PH, due to left heart disease, and Group 3 PH, associated with chronic lung disease, are the two most common forms [1] . While PH overall is not rare, Group 1 PH—also known as pulmonary arterial hypertension (PAH)—is a relatively rare disease [2] . Moreover, PAH represents one of the most challenging subtypes of PH, marked by its progressive nature and devastating impact on patient survival [3,4] . Despite therapeutic advances, PAH maintains a sobering prognosis, with transplant-free survival rates of only 57% at five years and 35% at ten years [5] . The disease’s initial non-specific presentation—including dyspnea, fatigue, and  \nJ. Mark. Access Health Policy 2026, 14, 9 [https://doi.org/10.3390/jmahp14010009](https://doi.org/10.3390/jmahp14010009)  \ndizziness—often leads to critical delays in diagnosis and treatment initiation, potentially compromising patient outcomes [3,4] .  \nAn emerging paradigm in PAH pathobiology draws striking parallels with cancer biology. Both conditions share fundamental molecular mechanisms, including deregulated cellular ","cbCailiLvfMTdV7T","https://ap.wps.com/l/cbCailiLvfMTdV7T","pdf",945487,17,"English","# Introduction\n# Materials and Methods\n## Study Design and Setting","[{\"question\":\"Why were parallels between PAH and cancer studied?\",\"answer\":\"PAH and cancer both have high mortality and complex prognoses, but PAH parallels may be underrecognized because PAH is relatively rare. Identifying similarities across domains could improve recognition among healthcare stakeholders.\"},{\"question\":\"How did the study identify cancer analogs for PAH?\",\"answer\":\"The four-step approach used inclusion/exclusion criteria to select potential analogs, categorized comparison characteristics (epidemiologic, clinical, therapeutic landscape, and HCRU), extracted data via a targeted literature review, and ranked similarity using absolute differences between cancer and PAH characteristics.\"},{\"question\":\"Were any cancers found to fully mirror PAH?\",\"answer\":\"No single cancer fully mirrored PAH. Instead, multiple analogs differed by domain, collectively reinforcing PAH’s multidimensional complexity and overlap with oncological conditions.\"}]","Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies | PDF",1790055388,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/364e21e55ce7d0e8a391fbbcf491f438.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0b60c170c3168461742182414ce9a90.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da0d965970db8c673f065840fa905b01.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e9360be5f846f918bdc4cc4fb3eec4b.webp",980,1385]